Table 3.
number of suspected nOPV2 AESIΩ reported by state, March 13 - July 7 2021, Nigeria
| No (%) of AESI | |||||
|---|---|---|---|---|---|
| State | Number reported AESI | Number vaccinated with nOPV2 | #Number ascertained as AESI | Number with symptom onset after vaccination | Number AESI abstracted |
| Bayelsa | 34 | 30 (88.2%) | 29 (85.3%) | 23 (67.5%) | 7 (20.6%) |
| Delta | 15 | 11 (73.3%) | 15 (100%) | 10 (66.7%) | - |
| FCT | 2 | 2 (100%) | 2 (100%) | 2 (100%) | - |
| Kebbi | 128 | 127 (99.2%) | 128 (100.0%) | 114 (89.1%) | 5 (3.9%) |
| Niger | 18 | 15 (3.3%) | 18 (100.0%) | 11 (61.1%) | - |
| Sokoto | 22 | 22 (100%) | 22 (100%) | 8 (36.4%) | - |
| Zamfara | 15 | 15 (100%) | 15 (100%) | 11 (73.3%) | - |
| Total | 234 | 223 (95.3%) | 229 (97.9%) | 179 (76.5%) | 12 (5.1%) |
#Number ascertained are total number of suspected cases presented to a medical doctor for review to ensure cases meet criteria for reporting as suspected AESI ΩNovel oral polio vaccine type 2 adverse event of special interest, FCT: federal capital territory